Compare Stocks

Enter up to five stock symbols separated by a comma or space (e.x BAC,WFC,JPM,LON:BARC).
 

 Matinas BioPharmaFennec PharmaceuticalsOncoCyteMedlab ClinicalBurcon NutraScience
SymbolNYSEAMERICAN:MTNBN/ANYSEAMERICAN:OCXASX:MDCTSE:BU
Price Information
Current Price$0.63N/A$2.22A$0.48C$1.82
52 Week RangeBuyBuyBuyN/ABuy
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/ABuy
Consensus Price Target$4.6875N/A$7.00N/AN/A
% Upside from Price Target644.05% upsideN/A215.32% upsideN/AN/A
Trade Information
Market Cap$102.33 millionC$128.33 million$115.38 million$103.38 millionC$160.46 million
BetaN/AN/AN/AN/AN/A
Average Volume865,7421,570645,194N/A589,999
Sales & Book Value
Annual RevenueN/AN/AN/A$5.43 millionC$49,033.00
Price / SalesN/AN/AN/A19.033,272.53
CashflowN/AN/AN/AA$0.05 per shareC$0.10 per share
Price / CashN/A7.35N/A8.8918.73
Book ValueN/AC$0.83 per shareN/AA$0.07 per shareC$0.14 per share
Price / BookN/AN/AN/A6.7613.19
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AC($0.67)N/AA($0.04)C($0.11)
Trailing P/E Ratio0.00N/A0.00N/AN/A
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A6.48%650.26%
Current RatioN/A12.96%N/A3.83%9.82%
Quick RatioN/A12.92%N/A3.06%9.70%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees15312N/AN/A
Shares Outstanding162.43 million19.90 million51.97 million215.36 million88.17 million
Next Earnings Date11/11/2019 (Estimated)11/12/2019 (Estimated)11/12/2019 (Estimated)N/A11/12/2019 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
 Matinas BioPharmaFennec PharmaceuticalsOncoCyteMedlab ClinicalBurcon NutraScience

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel